Abstract:Belatacept, a high-affinity variant of CTLA4-Ig, is a recently approved immunosuppressive agent for the prevention of acute rejection. It functions as a potent antagonist of the CD28-B7 interactions, thereby inhibiting T cell co-stimulation and activation. Experimental data involving the transient use of CTLA4-Ig to induce allograft tolerance have shaped the current paradigm that CTLA-4Ig is ineffective at inhibiting memory T cell responses, and by extension T-dependent alloantibody responses. This resistance is explained by the acquisition of additional activation-induced costimulatory molecules by memory T cells. We noted that the efficacy of CTLA4-Ig as a continuously administered drug for controlling rejection in sensitized recipients has not been investigated. Here we report on the efficacy of CTLA4-Ig in preventing acute rejection in sensitized C57BL/6 recipients that had received BALB/c spleen cell transfusion 3-6 months previously. We set up four experimental groups. Group 1 (N=5): sensitized mice with HTX and CTLA4-Ig treated (Day -2, Day 0, Day2, then weekly (1 mg/dose) Group 2 (N=3): sensitized mice with HTX and no CTLA4-Ig, Group 3: (N=10) naive mice with HTX and CTLA4-Ig treated, Group 4 (N=10): naive mice with HTX and no CTLA4-Ig. In the untreated Groups 2 & 4, allografts were rejected within 7 days post-transplantation, whereas in Group 3 of naive mice receiving CTLA4-Ig, all the grafts survived long-term (>90 days). In Group 1 of sensitized recipients receiving CTLA4-Ig, the allografts survived for 42, 42, 49, >90, >90 days. The pre-transplant donor-specific antibody (DSA) titers in the recipients that went on to reject their graft was significantly higher compared to those that accepted their grafts. Furthermore, DSA titers increased post-transplantation in the recipients that went on to reject their allografts, whereas DSA titers decreased in those that accepted their grafts. In conclusion, these observations illustrate the efficacy of CTLA-4Ig treatment at controlling rejection in sensitized recipients, and underscore the barrier pre-transplantation DSA poses to long-term graft acceptance. This experimental model also provides a unique opportunity for testing if DSA promotes antibody-mediated rejection or alloreactive memory T cell priming and T cell-mediated rejection in CTLA4-Ig treated recipients, and for identifying therapies that promote long-term graft survival in sensitized recipients.

Antigen-specific Killer Polylactic-Co-glycolic Acid Microspheres Selectively Deplete Antigen-Specific T Cells in Vitro and in Vivo (TRAN1P.924)

Antigen-specific killer polylactic-co-glycolic acid (PLGA) microspheres can prolong alloskin graft survival in a murine model.

A biodegradable killer microparticle to selectively deplete antigen-specific T cells in vitro and in vivo

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

An Antigen-Presenting and Apoptosis-Inducing Polymer Microparticle Prolongs Alloskin Graft Survival by Selectively and Markedly Depleting Alloreactive CD8+ T Cells

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

Killer artificial antigen-presenting cells treating skin allograft rejection and its impact on the overall immune function in mice model

Cell Communication‐Mediated Selective Drug Delivery for Epitope‐Specific Deletion of Alloreactive T Cells in Organ Transplant

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Specific Tolerance Induction of Allo-Kb-skin Grafts by FK506 in the CD8-depleted H-2k Recipients Required Low Amounts of Kb-antigen

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Efficient And Selective Prevention Of Graft-Versus-Host Disease By Ag-Specific Induced Regulatory T Cells In Mice

Ex Vivo Inhibition of NF-κB Signaling in Alloreactive T-cells Prevents Graft-Versus-Host Disease

Antibody-functionalized Peptidic Membranes for Neutralization of Allogeneic Skin Antigen-Presenting Cells.

The Role Of Selective Depletion Of Alloreactive Donor T Cells In Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation.

Design and Optimization of PLGA Particles to Deliver Immunomodulatory Drugs for the Prevention of Skin Allograft Rejection

Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen

Inhibition of Myeloid Differentiation Factor 88 Signaling Mediated by Histidine-Grafted Poly(Beta-Amino Ester) Ester Nanovector Induces Donor-Specific Liver Allograft Tolerance

Marked Prolongation of Cardiac Allograft Survival by Dendritic Cells Genetically Engineered with Nf-Kappa B Oligodeoxyribonucleotide Decoys and Adenoviral Vectors Encoding Ctla4-Ig

In Vivo Kidney Allograft Endothelial Specific Scavengers for On‐Site Inflammation Reduction under Antibody‐Mediated Rejection

Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation